| Interests in associates |
13.Interests in associates The following table shows the Company’s interests in associates of the Company which management considered to be material to the Company as of December 31, 2025 and 2024: | | | | | | | | | | | Interests in associates | | | | | | | | | | | in € K, except where otherwise specified | | | | | | | | | | | | | Country of | | Ownership | | Method of | | | | | Name of the entity | | incorporation | | interest in % | | measurement | | Carrying value | | | | | | | | | 2025 | | 2024 | | | | | | | | | | | | Vifor Fresenius Medical Care Renal Pharma Ltd. | | Switzerland | | 45 | | Equity method | | 632,026 | | 580,973 | Other associates | | | | | | | | 31,626 | | 39,858 | Equity method investees | | | | | | | | 663,652 | | 620,831 |
In December 2010, the Company and CSL Vifor formed a new renal pharmaceutical company, Vifor Fresenius Medical Care Renal Pharma Ltd., recognized as an equity method investee of which the Company owns 45%. Vifor Fresenius Medical Care Renal Pharma Ltd. develops and distributes products focused on addressing distinct complications and areas of chronic kidney disease, renal anemia management, mineral and bone management, kidney function preservation and improvement, conditions associated with kidney impairment and its treatment, and cardio-renal management. The following table contains the summarized financial information for Vifor Fresenius Medical Care Renal Pharma Ltd as of and for the year ended December 31, 2025 and 2024: | | | | | Summarized financial information | | | | | In € K | | | | | Summarized balance sheets | | 2025 | | 2024 | | | | | | Current assets | | 824,062 | | 914,502 | Non-current assets | | 439,909 | | 518,589 | Current liabilities | | 277,103 | | 480,640 | Non-current liabilities | | 32,534 | | 34,116 | Net assets | | 954,334 | | 918,335 |
| | | | | Reconciliation to carrying amounts (net assets) | | 2025 | | 2024 | | | | | | Opening balance net assets January 1, | | 918,335 | | 893,505 | Profit for the period | | 456,306 | | 290,766 | Other comprehensive income | | (3,428) | | (116,914) | Dividends paid | | (304,832) | | (205,301) | Foreign currency translation | | (112,047) | | 56,279 | Closing balance net assets December 31, | | 954,334 | | 918,335 | | | | | | Company’s share in net assets | | 429,450 | | 413,251 | Other reconciling items(1) | | 257,528 | | 219,166 | Eliminations | | (54,952) | | (51,444) | Carrying amount | | 632,026 | | 580,973 |
| | | | | | | For the year ended | | For the year ended | Summarized statement of comprehensive income | | December 31, 2025 | | December 31, 2024 | | | | | | Revenue | | 950,888 | | 741,183 | Profit from continuing operations | | 456,306 | | 290,766 | Profit for the period | | 456,306 | | 290,766 | Other comprehensive income | | (3,428) | | (116,914) | Total comprehensive income | | 452,878 | | 173,852 | | | | | | Dividends received | | 137,174 | | 92,386 |
| (1) | Includes Goodwill as well as impacts from foreign currency translation. |
|